Healthcare

The 10-year real yield (the return after inflation) jumped 24 basis points in 5 days to 2.85%. That rare 2.94 standard deviation move looks like a lasting shift. Healthcare stocks are favored as safe havens, but richly valued device makers like Intuitive Surgical carry rate risk investors are overlooking.

Medtronic raised FY2027 guidance on broad-based portfolio strength, signaling procedure volume recovery across cardiac, neuro, and surgical segments. XLV is selling off on macro fears while the underlying demand signal is constructive. Long procedure-volume-sensitive US mid-cap medical device makers into year-end.

Moderna/Merck's mRNA melanoma vaccine met both primary endpoints in Phase 3 — the first large-trial win for personalized mRNA oncology. The obvious trade (long MRNA) is already up ~90%. The non-obvious trade: US-listed CDMOs and LNP/raw-material suppliers that are structurally required to scale personalized mRNA manufacturing face a multi-year capacity buildout that the market hasn't priced.

CAH's GMPD segment fell 2.2% YoY to $3.13B. Bausch Health's own 10-K names Cardinal Health as a 14%-of-revenue customer. A shrinking GMPD channel mechanically implies lower Bausch product throughput. Bausch has not repriced; the signal arrived on CAH's ticker.

The FDA has approved Moderna's mRNA-based influenza vaccine, reversing an earlier refusal to even review the application following public outcry. This marks a significant regulatory milestone for Moderna's pipeline beyond COVID.

Eli Lilly reported Q2 2026 results that easily topped consensus estimates, driven by surging sales of Zepbound and Mounjaro. The company raised its full-year 2026 revenue guidance to $85-87B from the prior $82-85B range.

The FTC has sued Hims & Hers Health over alleged sharing of sensitive health data with Meta and Snap, deceptive billing practices, and difficult subscription cancellation processes. Shares fell ~10% on the news.

Curium is in advanced talks to acquire radiopharma company Lantheus Holdings in a deal valued at approximately $7 billion, with an announcement potentially coming within days, per people familiar with the matter.

Eli Lilly announced positive results from two additional late-stage trials of retatrutide, its next-generation obesity/GLP-1 drug, bringing total positive Phase 3 trials to five. Lilly confirmed it will file for regulatory approval in 2027, positioning retatrutide as the next pillar of its obesity franchise.

HHS froze $1B+ in Medicaid payments to CA and MN. States facing sudden funding shortfalls historically accelerate managed care outsourcing to shift fiscal risk. Long large-cap US Medicaid-focused managed care organizations — the structural beneficiaries of state budget stress that the market is treating as a sector-wide negative.

Medicare covering GLP-1 weight-loss drugs for seniors starting July 1 is bullish for pharma — but the market is already pricing that. The real trade is in cardiac monitoring and implantable device makers: GLP-1 adoption in seniors triggers mandatory cardiac workups, arrhythmia screening, and long-term device implants. Long large-cap cardiac device and diagnostics companies.

Eli Lilly reported positive late-stage clinical trial results for multiple next-generation obesity/diabetes drugs, including orforglipron (oral GLP-1 with no food/water restrictions) and retatrutide (triple-action), showing significant weight loss and additional benefits including sleep apnea reduction. Shares rose premarket on the data.

Eli Lilly presented clinical data on retatrutide (triple GIP/GLP-1/glucagon agonist) at the American Diabetes Association meeting, showing substantial reductions in blood sugar, body weight, knee osteoarthritis pain, and obstructive sleep apnea. Lilly's investor relations site confirmed the data release officially.

Pfizer's monthly injectable obesity drug (berobenatide) demonstrated a side-effect profile similar to Novo Nordisk's Wegovy in a midstage clinical trial. The data positions Pfizer as a credible competitor in the GLP-1 obesity market, with a once-monthly dosing advantage over weekly injectables.

Nasdaq's largest single-day drop ever wiped $1.8T from the S&P 500. Risk-parity and balanced funds are forced to mechanically rebalance out of tech into low-beta defensives. Healthcare and utilities are already leading — long large-cap defensive healthcare with domestic US revenue exposure into this rotation.